Eurofins Scientific

Eurofins Scientific increased group revenue in the third quarter by 6.1% to €1.91 billion and reported organic growth of 3.5%. Revenue in Europe rose 3.7% to €985 million, and in North America 7.9% to €712 million. For 2026 the company expects organic growth below its mid-single-digit target range, but aims to return to the targeted growth in 2027 and confirms an adjusted EBITDA margin of over 22.5%. The stock fell intraday after the more cautious outlook, but later reversed and again reached a 52-week high. » Więcej na deraktionaer.de

Ten years ago the closing price of Eurofins Scientific shares was €37.43, meaning a €10,000 investment would have bought about 267.165 shares. At the closing price on 11 September 2026 of €70.70, that investment would be worth €18,888.59, an increase of 88.89 percent. Eurofins Scientific most recently reached a market capitalization of €12.27 billion; stock splits and dividends were not taken into account in the calculation. » Więcej na finanzen.net

Eurofins Scientific recorded organic growth of 2.7% in the first half, below market expectations. Its biopharma business and CDMO activities showed weakness, while product testing remained stable. Revenue of €3.701 billion matched consensus; adjusted EBITDA of €877 million and a margin of 23.7% beat expectations. Adjusted earnings per share rose 25% to €1.64 and free cash flow improved significantly; the company confirms its full-year guidance with mid-single-digit organic growth and margin improvement. » Więcej na de.investing.com

Eurofins Scientific reported Q1 2026 revenue of USD 1.79 billion, missing the USD 1.81 billion forecast, weighed down by extreme weather in North America and northern Europe and by currency headwinds. The stock fell about 11.1% after the announcement and approached its 52-week low. Management remains confident it will achieve mid-single-digit organic growth and the planned margin expansion for the year through operational efficiency measures. » Więcej na de.investing.com

Eurofins reported for fiscal 2025 an increase in adjusted earnings per share of 24% to €2.31, with revenue up 5% to €7,296m and organic growth of 4.1% (3.9% H1 vs. 4.4% H2). Adjusted EBITDA rose 6% to €1,641m with a margin of 22.5%; free cash flow improved 9% to €876m. The company highlighted operational efficiency, working-capital improvements and continued M&A activity; net debt stands at 2.2x. For 2026 Eurofins expects mid-single-digit organic growth, and it confirmed its 2027 targets of 6.5% annual organic growth and a 24% adjusted EBITDA margin; the stock fell about 5% on the day of the release. » Więcej na de.investing.com